血友病A的非因素疗法:一种必不可少的药物实体
Rahul U Ramachandran1, Vishnu Sharma2, Shailendra P Verma3
1Pediatrics, National Health Mission (NHM) Kerala, Trivandrum, IND.
Cureus
|November 4, 2024
概括
将埃米齐祖马布添加到印度的必需药物清单中,可以改善获得血友病A治疗的机会. 这种非因子疗法为患者提供了具有成本效益和临床益处的结果,特别是在资源有限的环境中.
科学领域:
- 血液学 血液学 血液学
- 药物经济学 药物经济学
- 公共卫生 公共卫生
背景情况:
- 在资源有限的环境中,获得罕见疾病治疗是不公平的.
- 血友病A治疗面临传统因子替代的挑战.
- 埃米齐祖马布提供了一个非因子替代方案来解决药物管理和抑制剂的风险.
研究的目的:
- 审查印度血友病护理的现状.
- 巩固关于埃米齐祖马布在印度环境中的益处的证据.
- 倡导将埃米齐祖马布列入国家卫生使命的基本药物清单.
主要方法:
- 关于印度埃米齐祖马布研究的文献综述.
- 对成本效益和临床益处的分析.
- 评估对治疗准入和患者结果的影响.
主要成果:
- 艾米齐祖马布在印度证明了成本效益和临床益处.
- 将其列入必需药物清单将提高治疗的准入和遵守.
- 确保现有患者的治疗连续性,并改善高风险个体的治疗结果.
结论:
- 艾米齐祖马布被列入NHM必需药物清单对于印度公平的血友病A护理至关重要.
- 这一补充将减少医疗负担,并改善患者的治疗结果.
- 它保证了目前由NHM支持的患者的持续治疗.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
624
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
624
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Disorders of Hemostasis
716
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
716
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
477
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
477
Role of Hematopoietic Growth Factors
1.3K
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
Thrombopoietin (TPO), mainly released by the liver,...
1.3K
Extrinsic and Intrinsic Pathways of Hemostasis
5.8K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
5.8K


